Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIS793 plus gemcitabine and nab-paclitaxel versus placebo plus gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma
jRCT2031210394Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of nisevokitug in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Novartis. Primary endpoints: Incidence of dose-limiting toxicities and Overall survival. Started Nov 2021; status: completed.
02
Drugs
nisevokitug
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031210394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210394.